INTRODUCTION AND OBJECTIVES: The most common lifestyle preventative treatment of stone disease is increasing fluid intake. However, many patients experience lower urinary tract symptoms (LUTS) that may impair their ability to increase fluid intake. The objective of this study is to determine if there is a correlation between International Prostate Symptom Scores (IPSS) and 24-hour urine collection volumes.
METHODS: We retrospectively reviewed all kidney stone patients over a 2 year period who were given IPSS questionnaires at the time of their initial consultation, and their subsequent 24-hr urine collections. Exclusion criteria included symptomatic stone or urinary tract infection at time of IPSS completion, inadequate 24-hour collection, or incomplete IPSS questionnaire. RESULTS: Overall, 131 patients met inclusion criteria, with a mean age of 53 years. Stratification by IPSS score into mild (0-7), moderate (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , and severe (20-35) yielded groups of N¼96, 28, and 7, respectively. Linear regression modelling did not reveal a correlation between IPSS score and volume (p¼0.1). There was no difference between urine volumes in the mild, moderate and severe groups (p¼0.07). However, when comparing those with severe LUTS to the rest of the population, they showed significantly lower daily urine volumes (mean 1.4 L/day vs 2.0 L/day; p¼0.02). When patients with low urine outputs (1 L/day) (N¼1F:9M, mean age 54 years old), were compared to those adequate urine volumes (2 L/day) (N¼6F:59M, mean age 52 years old), a significantly higher overall IPSS score was noted (11.7 vs. 6.1; p¼0.04). Low output patients reported significantly higher scores on the questions related to incomplete emptying (1.8 vs. 0.7; p¼0.03), intermittency (1.7 vs. 0.6; p¼0.01), and straining (1.8 vs. 0.4; p¼0.002).
CONCLUSIONS: This study is the first to examine the correlation between IPSS score and 24-hour urine volume. Though our data does not show a linear relationship between urine output and IPSS; those with lower urine volumes (1 L/day) have significantly worse self reported voiding symptoms when compared to those with adequate volumes (2 L/day) for stone prevention.
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MP90-06 DOES THIAZIDE USE FOR STONE PREVENTION AFFECT OUR PATIENTS' HEALTH-RELATED QUALITY OF LIFE?
Eric Raffin*, Lebanon, NH; Kristina Penniston, Stephen Nakada, Madison, WI; Jodi Antonelli, Dallas, TX; Davis Viprakasit, Chapel Hill, NC; Timothy Averch, Pittsburgh, PA; Sri Sivalingam, Cleveland, OH; Roger Sur, San Diego, CA; Ben Chew, Vancouver, Canada; Vincent Bird, Gainesville, FL; Lawrence Dagrosa, Rebecca Smith, Vernon Pais, Lebanon, NH INTRODUCTION AND OBJECTIVES: Patients often express concerns about the burden of chronic medication use for stone prevention despite its association with decreased stone recurrence. Fatigue and sexual side effects are among such concerns of patients starting thiazide diuretics. However, it is unknown how the use of thiazides affects the health-related quality of life (HRQOL) of stone formers. We evaluated the effect of thiazides on patients' stone-related HRQOL.
METHODS: Utilizing the previously validated Wisconsin Stone QOL questionnaire (WISQOL), we analyzed cross-sectional data from patients both new to and established in stone prevention who were enrolled at sites participating in the North American Stone Quality of Life Consortium. We compared HRQOL in the domains of social impact, emotional impact, disease impact, and vitality in patients prescribed thiazides against those not using student's t-test. We performed multivariate linear regression controlling for age, gender, BMI, and number of stone events to confirm the significance of any differences. Additionally, we assessed with univariate and multivariate logistic regression the likelihood of complaints of fatigue and reduced sexual interest/activity between those prescribed and not prescribed thiazides.
RESULTS: 1511 stone formers were included (787 M, 724 F), of whom 207 were on a thiazide at study enrollment. Patients prescribed a thiazide had significantly higher scores (better HRQOL) in each domain compared to those not prescribed a thiazide. These differences maintained significance with multivariate analysis (mean domain scores higher by 1.9, 2.3, 2.1, 1.0 points, respectively, all p<0.01). Patients prescribed thiazides were less likely than those not prescribed to report any fatigue in the last 4 weeks (59% vs 68%, p¼0.008). Those on thiazides were less likely to report reduced sexual interest/activity (24% vs 31%, p¼0.02). On multivariate logistic regression, patients on thiazides were overall 32% less likely to report fatigue, p¼0.02, and 33% less likely to report reduced sexual interest/activity, p¼0.026, when controlling for the aforementioned factors.
CONCLUSIONS: Patients prescribed thiazide diuretics for stone prevention demonstrated better HRQOL compared to patients not prescribed one. Specifically, thiazide use was not associated with fatigue or reduced sexual interest/activity. These findings may provide reassurance to patients being counseled on starting thiazides for medical management of stones.
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Eric Raffin*, Lebanon, NH; Kristina Penniston, Stephen Nakada, Madison, WI; Jodi Antonelli, Dallas, TX; Davis Viprakasit, Chapel Hill, NC; Timothy Averch, Pittsburgh, PA; Sri Sivalingam, Cleveland, OH; Roger Sur, San Diego, CA; Ben Chew, Vancouver, Canada; Vincent Bird, Gainesville, FL; Lawrence Dagrosa, Rebecca Smith, Vernon Pais, Lebanon, NH INTRODUCTION AND OBJECTIVES: Potassium citrate has an established role in medical management of stone disease but many patients have reported unwanted side effects, notably gastrointestinal (GI). It is not currently well understood how the benefits of potassium citrate affect patients' health-related quality of life (HRQOL). We sought to evaluate the effect of potassium citrate on patients' stone-related HRQOL.
METHODS: Utilizing the previously validated Wisconsin Stone-QOL questionnaire (WISQOL), a kidney stone-specific instrument, we analyzed cross-sectional data from patients both new to and already established in stone prevention who were enrolled at sites participating in the North American Stone Quality of Life Consortium. We compared HRQOL in the WISQOL domains of social impact, emotional impact, disease impact, and vitality between patients prescribed potassium citrate and those not. In addition to student's t-test, multivariate linear regression controlling for age, gender, BMI, and number of stone events was performed to determine the strength of any differences found. Additionally, univariate and multivariate logistic regression were used to assess the likelihood of complaints of nausea and stomach upset or cramps between those prescribed and not prescribed potassium citrate.
RESULTS: 1511 stone formers were included (787 male, 724 female), of whom 258 were on potassium citrate at study enrollment. Patients prescribed potassium citrate scored significantly higher (better e1212 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 
